Company Analysis Veracyte, Inc.
1. Summary
Advantages
- Price (33.46 $) is less than fair price (44.87 $)
- The stock's return over the last year (40.77%) is higher than the sector average (-27.93%).
- Current debt level 1.11% is below 100% and has decreased over 5 years from 4.94%.
Disadvantages
- Dividends (0%) are below the sector average (0.5351%).
- The company's current efficiency (ROE=-7.13%) is lower than the sector average (ROE=9.78%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Veracyte, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -20.5% | -21.5% | -5.3% |
| 90 days | -22% | -28.6% | -3.5% |
| 1 year | 40.8% | -27.9% | 15.9% |
VCYT vs Sector: Veracyte, Inc. has outperformed the "Healthcare" sector by 68.7% over the past year.
VCYT vs Market: Veracyte, Inc. has outperformed the market by 24.85% over the past year.
Stable price: VCYT is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: VCYT with weekly volatility of 0.784% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (33.46 $) is lower than the fair price (44.87 $).
Price significantly below the fair price: The current price (33.46 $) is 34.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.27).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.14).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.97) is lower than that of the sector as a whole (4.64).
P/BV vs Market: The company's P/BV (1.97) is lower than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.69) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (5.69) is lower than that of the market as a whole (10.29).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (122.3) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (122.3) is higher than that of the market as a whole (25.46).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 23.26% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (23.26%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (106.41%).
5.4. ROE
ROE vs Sector: The company's ROE (-7.13%) is lower than that of the sector as a whole (9.78%).
ROE vs Market: The company's ROE (-7.13%) is lower than that of the market as a whole (8.96%).
5.5. ROA
ROA vs Sector: The company's ROA (-6.54%) is lower than that of the sector as a whole (0.33%).
ROA vs Market: The company's ROA (-6.54%) is lower than that of the market as a whole (6.33%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-4.59%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-4.59%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5351%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 27.11.2024 | Wygant Jonathan VP, Chief Accounting Officer |
Sale | 42.89 | 215 822 | 5 032 |
| 07.08.2024 | Evan Jones Director |
Purchase | 27.05 | 1 620 400 | 59 904 |
| 19.07.2023 | JONES EVAN/ FA Director |
Sale | 30.17 | 93 225 | 3 090 |
| 19.07.2023 | JONES EVAN/ FA Director |
Sale | 30.14 | 25 257 | 838 |
| 14.06.2022 | Holstein Jens Director |
Sale | 16.27 | 141 874 | 8 720 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
